Page last updated: 2024-09-03

vadimezan and Pancreatic Neoplasms

vadimezan has been researched along with Pancreatic Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dwinell, MB; Gershan, J; Jing, W; Johnson, BD; McAllister, D; Palen, K; Riese, MJ; Vonderhaar, EP	1

Other Studies

1 other study(ies) available for vadimezan and Pancreatic Neoplasms

Article	Year
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. Journal for immunotherapy of cancer, 2019, 04-29, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Female; Homeodomain Proteins; Humans; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Membrane Proteins; Mice; Mice, Knockout; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Burden; Tumor Escape; Tumor Microenvironment; Xanthones	2019

Article

Year

STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.

Journal for immunotherapy of cancer, 2019, 04-29, Volume: 7, Issue:1

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Female; Homeodomain Proteins; Humans; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Membrane Proteins; Mice; Mice, Knockout; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Burden; Tumor Escape; Tumor Microenvironment; Xanthones

2019